Suzuki, R <br/><br/>
Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.  [electronic resource] 

 -  Leukemia  Feb 2015 
 - 510-4 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2014.300  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Apoptosis<br/>Benzamides--administration & dosage<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Cell Line<br/>Cell Line, Tumor<br/>Cell Proliferation<br/>Cell Survival<br/>Drug Screening Assays, Antitumor<br/>HSP90 Heat-Shock Proteins--antagonists & inhibitors<br/>Humans<br/>Mice<br/>Mice, SCID<br/>Monomeric GTP-Binding Proteins--metabolism<br/>Multiple Myeloma--drug therapy<br/>Mutation<br/>Neoplasm Transplantation<br/>Pyrazines--administration & dosage<br/>Pyrazoles--administration & dosage<br/>Retinal Pigment Epithelium--cytology